CN113382717A - 局部braf抑制剂组合物用于治疗放射性皮炎的用途 - Google Patents

局部braf抑制剂组合物用于治疗放射性皮炎的用途 Download PDF

Info

Publication number
CN113382717A
CN113382717A CN202080012207.4A CN202080012207A CN113382717A CN 113382717 A CN113382717 A CN 113382717A CN 202080012207 A CN202080012207 A CN 202080012207A CN 113382717 A CN113382717 A CN 113382717A
Authority
CN
China
Prior art keywords
grade
adverse
composition
rtog
nci
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080012207.4A
Other languages
English (en)
Chinese (zh)
Inventor
诺阿·舍拉赫
诺阿·洛文顿-施皮尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lutris Pharma Ltd
Original Assignee
Lutris Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lutris Pharma Ltd filed Critical Lutris Pharma Ltd
Publication of CN113382717A publication Critical patent/CN113382717A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202080012207.4A 2019-02-12 2020-02-11 局部braf抑制剂组合物用于治疗放射性皮炎的用途 Pending CN113382717A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962804235P 2019-02-12 2019-02-12
US62/804,235 2019-02-12
PCT/IB2020/051073 WO2020165755A1 (en) 2019-02-12 2020-02-11 Use of topical braf inhibitor compositions for treatment of radiation dermatitis

Publications (1)

Publication Number Publication Date
CN113382717A true CN113382717A (zh) 2021-09-10

Family

ID=72044789

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080012207.4A Pending CN113382717A (zh) 2019-02-12 2020-02-11 局部braf抑制剂组合物用于治疗放射性皮炎的用途

Country Status (17)

Country Link
US (1) US11439648B2 (https=)
EP (1) EP3923911B1 (https=)
JP (1) JP2022519675A (https=)
KR (1) KR102534457B1 (https=)
CN (1) CN113382717A (https=)
AU (1) AU2020220895B9 (https=)
BR (1) BR112021015137A2 (https=)
CA (1) CA3127175C (https=)
ES (1) ES2952251T3 (https=)
HR (1) HRP20231241T1 (https=)
HU (1) HUE063091T2 (https=)
IL (1) IL285560B2 (https=)
MX (1) MX2021009535A (https=)
PL (1) PL3923911T3 (https=)
RS (1) RS64618B1 (https=)
WO (1) WO2020165755A1 (https=)
ZA (1) ZA202106581B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023051685A1 (zh) * 2021-09-30 2023-04-06 北京大学 一种对红系前体细胞或成红细胞进行扩增的方法及其应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116669739A (zh) * 2020-12-24 2023-08-29 鲁特里斯制药有限公司 用于治疗egfr下游效应物诱导的反应的局部braf抑制剂组合物
MX2024000227A (es) * 2021-07-02 2024-04-16 Lutris Pharma Ltd Uso de isoquinolina-1,5-diaminas para la curacion de heridas.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106535900A (zh) * 2014-05-06 2017-03-22 加利福尼亚大学董事会 使用braf抑制剂的伤口愈合
CN109069511A (zh) * 2016-03-10 2018-12-21 鲁特里斯制药有限公司 Braf抑制剂用于治疗皮肤反应的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753612A (en) 1992-10-27 1998-05-19 Yissum Research Development Co. Of The Hebrew University Of Jerusalem Pharmaceutical composition and method for inhibiting hair growth by administration of activin or activin agonists
US7989461B2 (en) 2005-12-23 2011-08-02 Amgen Inc. Substituted quinazolinamine compounds for the treatment of cancer
US8557830B2 (en) 2007-06-07 2013-10-15 Amgen Inc. RAF kinase modulators and methods of use
EP3147281A1 (en) * 2008-03-17 2017-03-29 Ambit Biosciences Corporation Quinazoline derivatives as raf kinase modulators and methods of use thereof
WO2011117381A1 (en) * 2010-03-26 2011-09-29 Boehringer Ingelheim International Gmbh B-raf kinase inhibitors
US20130226549A1 (en) 2012-02-27 2013-08-29 Yufeng J. Tseng Structure-based fragment hopping for lead optimization and improvement in synthetic accessibility
KR20140011780A (ko) 2012-07-19 2014-01-29 한미약품 주식회사 단백질 키나아제 저해활성을 갖는 이소퀴놀린-5-카복스아미드 유도체
JP6912667B2 (ja) * 2017-07-29 2021-08-04 ルトリス ファーマ エル ティー ディー． 新規なｂｒａｆ阻害剤および皮膚反応を治療するためのその使用
WO2019032717A1 (en) * 2017-08-08 2019-02-14 Memorial Sloan Kettering Cancer Center USE OF BRAF INHIBITORS FOR TREATING SKIN REACTIONS CAUSED BY TREATMENT WITH MEK INHIBITOR

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106535900A (zh) * 2014-05-06 2017-03-22 加利福尼亚大学董事会 使用braf抑制剂的伤口愈合
CN109069511A (zh) * 2016-03-10 2018-12-21 鲁特里斯制药有限公司 Braf抑制剂用于治疗皮肤反应的用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANKER, C等: "Avoiding severe toxicity from combined braf inhibitor and radiation treatment consensus guidelines from the eastern cooperative oncology group (ecog)", INT J RADIAT ONCOL BIOL PHYS,, vol. 95, no. 2, 9 November 2016 (2016-11-09), pages 632 - 646 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023051685A1 (zh) * 2021-09-30 2023-04-06 北京大学 一种对红系前体细胞或成红细胞进行扩增的方法及其应用

Also Published As

Publication number Publication date
WO2020165755A1 (en) 2020-08-20
PL3923911T3 (pl) 2023-12-27
ES2952251T3 (es) 2023-10-30
US20210346389A1 (en) 2021-11-11
BR112021015137A2 (pt) 2021-09-28
HRP20231241T1 (hr) 2024-02-16
EP3923911A4 (en) 2022-11-09
HUE063091T2 (hu) 2024-01-28
EP3923911B1 (en) 2023-07-12
JP2022519675A (ja) 2022-03-24
ZA202106581B (en) 2022-09-28
IL285560B2 (en) 2024-04-01
CA3127175C (en) 2023-06-27
AU2020220895A1 (en) 2021-08-12
CA3127175A1 (en) 2020-08-20
RS64618B1 (sr) 2023-10-31
AU2020220895B2 (en) 2022-11-17
AU2020220895B9 (en) 2023-02-02
IL285560A (en) 2021-09-30
IL285560B1 (en) 2023-12-01
KR20210126665A (ko) 2021-10-20
EP3923911A1 (en) 2021-12-22
KR102534457B1 (ko) 2023-05-18
MX2021009535A (es) 2022-10-10
US11439648B2 (en) 2022-09-13
EP3923911C0 (en) 2023-07-12

Similar Documents

Publication Publication Date Title
CA2301009C (en) Skin care compositions and use
US11439648B2 (en) Use of topical BRAF inhibitor compositions for treatment of radiation dermatitis
WO2025090117A1 (en) Compositions and methods for treatment of wounds and inflammatory skin conditions
EP2854784B1 (en) Method for treating skin inflammatory diseases
TWI630921B (zh) 含埃克替尼的皮膚外用藥物組合物及其應用
KR20230139402A (ko) 염증성 피부 증후군을 치료하는 약제학적인 용도의 화장품 조성물
EP4716539A1 (en) Pharmaceutical composition
WO2017129108A1 (zh) 一种用于治疗皮肤病的硅凝胶
RU2812708C2 (ru) Применение композиций на основе ингибитора braf для наружного применения для лечения лучевого дерматита
CN104546880B (zh) 一种治疗面部脂溢性皮炎的外用制剂
AU2004262934A1 (en) Topical composition comprising terbinafine and hydrocortisone
CN112007039B (zh) 一种包含氟西汀和维生素d3或其衍生物的组合物，及其应用
JP5460766B2 (ja) 外用医薬組成物
CN110944649B (zh) 鼠李糖及其衍生物作为抗真菌剂的用途
US20250114362A1 (en) Methods and compositions for treatment of cutaneous proliferative disorders and other skin conditions
JP2001163783A (ja) 皮膚疾患治療用外用剤
JP2002241308A (ja) 皮膚そう痒症治療薬
WO2011101868A2 (en) Stable pharmaceutical preparations containing clindamycin and benzoyl peroxide and method thereof
JP3568881B2 (ja) 皮膚疾患治療用外用剤
CN109381483A (zh) 一种治疗皮肤病的药物
JP3538367B2 (ja) 皮膚組織障害治療・予防・改善用外用剤
CN119403561A (zh) 用于预防和治疗潮湿相关性皮肤损伤的组合物
CN105582062A (zh) 一种苦荞麸皮提取物及包含该提取物的皮肤外用制剂
CN118175997A (zh) 活性抑制和/或产生抑制剂
CN107157993A (zh) 一种治疗皮肤干燥的药物组合物及其制备方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination